“I would like to see a diabetes management system like this become standard in GP medicine as part of digitalization and telemedicine.”
Dr. Marco Krüger, specialist in general medicine, Gnoien
ESYSTA is a medical device and automatically keeps a complete, precise diabetes diary for its users. Based on this reliable data, treatment teams can optimally adapt the individual diabetes therapies of their patients. Application errors and misunderstandings can be identified and eliminated more easily – to the benefit of the diabetes patient and to the delight of the treatment team.
ESYSTA reduces elevated HbA1c levels in type 2 diabetics by up to 2% – without increasing the risk of hypoglycaemia.
This was shown in a study conducted with over 200 patients and in collaboration with a health insurance company and the Technical University of Dresden.
Our customer service will be happy to send you the complete study on request.
All ESYSTA devices, the ESYSTA portal and the ESYSTA app are certified medical devices in accordance with the requirements of Directive 93/42/EEC (Medical Device Directive, MDD).
Like other medical aids, they are reimbursed by all health insurance companies.
As all ESYSTA components, including the app and the portal, are medical devices, you can make legally compliant treatment recommendations based on your data.
ESYSTA keeps your patients’ diabetes diaries and prepares the values clearly. If the ESYSTA devices are connected, this is also fully automatic, error-free and reliable.
For diabetes patients whose values you can access in the ESYSTA portal, no practice appointments are required to submit the diary – you can replace these with telephone calls.
ESYSTA meets the highest IT security standard in accordance with ISO/IEC 27001.
All data collected and secured via ESYSTA is considered medical data and is therefore specially protected.
It is transmitted and stored in encrypted form on high-security servers in Germany.
The data stored in the portal never leaves Germany.
Emperra is currently preparing a remunerated observational study to start in 2024. This study will serve to generate further “real world evidence” for ESYSTA and, with your help, will also be further adapted to your needs by collecting user experiences.
Together, all participants will make a valuable scientific contribution to ensuring that digital health applications can be used even better and in a more targeted manner.
Please contact us using the contact details provided if you are already interested. We will inform you in good time as soon as this application observation begins.
Simply contact our customer service if you have any questions, would like more information about ESYSTA, a demonstration of the devices or on-site training. We will also be happy to answer any questions you may have about the day-to-day use of the ESYSTA portal.
We are also happy to answer technical questions on the subject of diabetes mellitus and, if necessary, put you in touch with doctors who have already gained experience with ESYSTA.
Patients
Doctors
ESYSTA
Languages
Social
Copyright by Empera GmbH E-Health Technologies 2019. All rights reserved.
Copyright by Empera GmbH E-Health Technologies 2019. All rights reserved.